JOHN S. HYDE, M.D.
Since 1965 cromolyn sodium1 has been subjected to extensive pharmacological and clinical investigation in animals and man. The drug has no intrinsic bronchodilator, antihistaminic, or steroid-like properties. It appears to act by protecting the mast cell membrane and inhibiting the release of spasmogenic mediators that occur during antigen-antibody reactions and when triggered by certain seemingly nonimmunological mechanisms, such as exercise or hyperventilation (1).
In the treatment of asthma, cromolyn sodium is given by inhalation, by a capsule containing 20 mg of drug per dose, in a special turbo-inhaler device, the Spinhaler. A recent study has further clarified the fate of
HYDE JS. Cromolyn Prophylaxis for Chronic Asthma. Ann Intern Med. ;78:966. doi: 10.7326/0003-4819-78-6-966
Download citation file:
Published: Ann Intern Med. 1973;78(6):966.
Asthma, Pulmonary/Critical Care.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use